The global Memantine Market is estimated to be valued at US$ 565.93 Bn in 2022 and is expected to exhibit a CAGR of 3.87% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Memantine is a prescription drug used for the treatment of moderate to severe Alzheimer's disease. It belongs to a class of drugs called NMDA receptor antagonists. Memantine works by regulating glutamate activity in the brain which can be overstimulated in Alzheimer's disease, potentially damaging or killing neurons. The medication is available in both branded and generic forms as immediate-release tablets and oral solutions. It provides cognitive benefits for Alzheimer's patients by improving or stabilizing symptoms such as memory loss, impaired thinking, and inability to carry out daily tasks. The demand for memantine products is driven by the growing Alzheimer's disease patient population worldwide coupled with the lack of disease-modifying treatments.
Market key trends:
One of the key trends in the memantine market is the launch and approval of new generic versions. As the patents for major branded memantine drugs like Namenda expired in recent years, several generic manufacturers entered the market. For instance, in 2020, the US FDA approved multiple generic versions of the oral solution formulation. Increased generic competition has significantly brought down the prices of memantine treatments, improving their affordability and accessibility for Alzheimer's patients globally. This is expected to boost the volume growth of the memantine market during the forecast period.
Porter's Analysis
Threat of new entrants: The threat of new entrants to the memantine market is low as it requires significant investment in R&D, license and patent protection.
Bargaining power of buyers: The bargaining power of buyers is moderate as the memantine industry has a significant number of large buyers. However, switching costs are relatively low.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to the high dependence of memantine manufacturers on raw material suppliers.
Threat of new substitutes: The threat of new substitutes is moderate as memantine faces competition from alternative treatment options. However, memantine is still considered an important drug with few close substitutes.
Competitive rivalry: The competitive rivalry in the memantine market is high owing to the presence of many players operating at global and regional level.
Key Takeaways
The Global Memantine Market is expected to witness high growth, exhibiting CAGR of 3.87% over the forecast period, due to increasing prevalence of Alzheimer's disease and other dementias.
Regional analysis: North America is expected to dominate the memantine market during the forecast period. This is attributed to growing awareness regarding Alzheimer's disease treatment and increasing R&D efforts for novel therapies. Asia Pacific is anticipated to witness the fastest growth owing to rising geriatric population.
Key players: Key players operating in the memantine market are Allergan, Merz Pharma, Laboratorio Teuto Brasileiro, Lundbeck, Novartis, and Johnson & Johnson. Lundbeck's Namenda (memantine) is a leading brand in the United States.
Read More:
